|
1
|
Egenvall A, Bonnett BN, Ohagen P, Olson P,
Hedhammar A and Von Euler H: Incidence of and survival after
mammary tumors in a population of over 80,000 insured female dogs
in Sweden from 1995 to 2002. Prev Vet Med. 69:109–127. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lana SE, Rutteman GR and Withrow SJ:
Tumors of the mammary glandSmall Animal Clinical Oncology. 4th.
Withrow SJ and MacEwen EG: WB Saunders; Missouri: pp. 619–633.
2007, View Article : Google Scholar
|
|
3
|
Sorenmo KU, Worley DR and Goldschmidt MH:
Tumors of the mammary glandSmall Animal Clinical Oncology. 5th.
Withrow SJ, Vail DM and Page RL: Elsevier; Missouri: pp. 537–556.
2013
|
|
4
|
De Nardi AB, Raposo-Ferreira TMM and da
Assunção KA: Neoplasias MamáriasOncologia em Cães e Gatos. 2nd.
Daleck CR and De Nardi AB: Editora Roca; Rio de Janeiro: pp.
726–756. 2016
|
|
5
|
Sleeckx N, de Rooster H, Veldhuis Kroeze
EJ, van Ginneken C and van Brantegem L: Canine mammary tumours, an
overview. Reprod Domest Anim. 46:1112–1131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brody RS, Goldschimidt MA and Rosze J:
Canine mammary gland neoplasia. J Am Anim Hosp Assoc. 19:61–90.
1985.
|
|
7
|
Al Dissi AN, Haines DM, Singh B and Kidney
BA: Immunohistochemical expression of vascular endothelial growth
factor and vascular endothelial growth factor receptor-2 in canine
simple mammary gland adenocarcinomas. Can Vet J. 5:1109–1114.
2010.
|
|
8
|
Oliveira Filho JC, Kommers GD, Masuda EK,
Marques MF, Fighera RA, Irigoyen LF and Barros CL: Estudo
restrospectivo de 1.647 tumores mamários em cães. Pesq Vet Bras.
30:177–185. 2010. View Article : Google Scholar
|
|
9
|
Feliciano MA, Silva AS, Peixoto RVR,
Galera PD and Vicente WR: Estudo clínico, histopatológico e
imunoistoquímico de neoplasias mamárias em cadelas. Arq Bras Med
Vet Zootec. 64:1094–1100. 2012. View Article : Google Scholar
|
|
10
|
Zuccari DA, Pavam MV, Terzian AC, Pereira
RS, Ruiz CM and Andrade JC: Immunohistochemical evaluation of
e-cadherin, Ki-67 and PCNA in canine mammary neoplasias:
Correlation of prognostic factors and clinical outcome. Pesq Vet
Bras. 28:208–215. 2008. View Article : Google Scholar
|
|
11
|
Manuali E, De Giuseppe A, Feliziani K,
Fortes K, Casciari C and Marchesi MC: CA 15-3 cell lines and tissue
expression in canine mammary cancer and the correlation between
serum levels and tumour histological grade. BMC Vet Res. 8:862012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cassali GD, Lavalle GE, de Nardi AB,
Ferreira E, Bertagnolli AC, Estrela-Lima A, Alessi AC, Daleck CR,
Salgado BS, Fernandes CG, et al: Consensus for the diagnosis,
prognosis and treatment of canine mammary tumors-2013. Brazilian J
Vet Pathol. 7:38–69. 2013.
|
|
13
|
Yoshida K, Yoshida S, Choisunirachon N,
Saito T, Matsumoto K, Saeki K, Mochizuki M, Nishimura R, Sasaki N
and Nakagawa T: The relationship between clinicopathological
features and expression of epithelial and mesenchymal markers in
spontaneous canine mammary gland tumors. J Vet Med Sci.
76:1321–1327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cassali GD, Lavalle GE, De Nardi AB,
Ferreira E, Bertagnolli AC, Lima AE, Alessi AC, Daleck CR, Salgado
B, Fernandes CG, et al: Consensus for the diagnosis, prognosis and
treatment of canine mammary tumors. Brazilian J Vet Pathol.
4:153–180. 2011.
|
|
15
|
Hampe JF and Misdorp W: Tumors and
dysplasias of the mammary gland. Bull World Health Organ.
50:111–133. 1974.PubMed/NCBI
|
|
16
|
Monlux AW, Roszel JF, Macvean DW and
Palmer TW: Classification of epithelial canine mammary tumours in a
defined population. Vet Pathol. 14:194–217. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Misdorp W: Histologic classification and
further characterization of tumors in domestic animals. Adv Vet Sci
Comp Med. 20:191–221. 1976.PubMed/NCBI
|
|
18
|
Goldschmidt M, Peña L, Rasotto R and
Zappulli V: Classification and grading of canine mammary tumors.
Vet Pathol. 48:117–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zaha DC: Significance of
immunohistochemistry in breast cancer. World J Clin Oncol.
5:382–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blows FM, Driver KE, Schmidt MK, Broeks A,
van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO,
Blomqvist C, et al: Subtyping of breast cancer by
immunohistochemistry to investigate a relationship between subtype
and short and long term survival: A collaborative analysis of data
for 10,159 cases from 12 studies. PLoS Med. 7:e10002792010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dai X, Xiang L, Li T and Bai Z: Cancer
hallmarks, biomarkers and breast cancer molecular subtypes. J
Cancer. 7:1281–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perou CM and Børresen-Dale AL: Systems
biology and genomics of breast cancer. Cold Spring Harb Perspect
Biol. 3:a0032932011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peña L, Gama A, Goldschmidt MH, Abadie J,
Benazzi C, Castagnaro M, Díez L, Gärtner F, Hellmén E, Kiupel M, et
al: Canine mammary tumors: A review and consensus of standard
guidelines on epithelial and myoepithelial phenotype markers, HER2,
and hormone receptor assessment using immunohistochemistry. Vet
Pathol. 51:127–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sassi F, Benazzi C, Castellani G and Sarli
G: Molecular-based tumour subtypes of canine mammary carcinomas
assessed by immunohistochemistry. BMC Vet Res. 6:52010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gama A, Alves A and Schmitt F:
Identification of molecular phenotypes in canine mammary carcinomas
with clinical implications: Application of the human
classification. Virchows Arch. 453:123–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sorlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cirqueira MB, Moreira MARM, Soares LR and
Freitas-Júnior R: Subtipos moleculares do câncer de mama. Femina.
39:499–503. 2011.
|
|
29
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Meisel JL, Venur VA, Gnant M and Carey L:
Evolution of targeted therapy in breast cancer: Where precision
medicine began. Am Soc Clin Oncol Educ Book. 38:78–86. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rivenbark AG, O'Connor SM and Coleman WB:
Molecular and cellular heterogeneity in breast cancer: Challenges
for personalized medicine. Am J Pathol. 183:1113–1124. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ignatiadis M and Sotiriou C: Luminal
breast cancer: From biology to treatment. Nat Rev Clin Oncol.
10:494–506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arteaga CL, Sliwkowski MX, Osborne CK,
Perez EA, Puglisi F and Gianni L: Treatment of HER2-positive breast
cancer: Current status and future perspectives. Nat Rev Clin Oncol.
9:16–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fabi A, Malaguti P, Vari S and Cognetti F:
First-line therapy in HER2 positive metastatic breast cancer: Is
the mosaic fully completed or are we missing additional pieces? J
Exp Clin Cancer Res. 35:1042016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Figueroa-Magalhães MC, Jelovac D, Connolly
R and Wolff AC: Treatment of HER2-positive Breast Cancer. Breast.
23:128–136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mendes D, Alves C, Afonso N, Cardoso F,
Passos-Coelho JL, Costa L, Andrade S and Batel-Marques F: The
benefit of HER2-targeted therapies on overall survival of patients
with metastatic HER2-positive breast cancer-a systematic review.
Breast Cancer Res. 17:1402015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sharma P: Biology and management of
patients with triple-negative breast cancer. Oncologist.
21:1050–1062. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lebert JM, Lester R, Powell E, Seal M and
McCarthy J: Advances in the systemic treatment of triple-negative
breast cancer. Curr Oncol. 25 (Suppl 1):S142–S150. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vieira DS, Dufloth RM, Schmitt FC and
Zeferino LC: Breast cancer: New concepts in classification. Rev
Bras Ginecol Obstet. 30:42–47. 2008.(In Portuguese). View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Braunstein LZ and Taghian AG: Molecular
phenotype, multigene assays, and the locoregional management of
breast cancer. Semin Radiat Oncol. 26:9–16. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chan KK, Matchett KB, McEnhill PM, Dakir
el H, McMullin MF, El-Tanani Y, Patterson L, Faheem A, Rudland PS,
McCarron PA and El-Tanani M: Protein deregulation associated with
breast cancer metastasis. Cytokine Growth Factor Rev. 26:415–423.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baranwal S and Alahari SK: Molecular
mechanisms controlling E-cadherin expression in breast cancer.
Biochem Biophys Res Commun. 384:6–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matos AJ, Lopes C, Carvalheira J, Santos
M, Rutteman GR and Gärtner F: E-cadherin expression in canine
malignant mammary tumours: Relationship to other
Clinico-pathological variables. J Comp Pathol. 134:182–189. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sorenmo K: Canine mammary gland tumors.
Vet Clin North Am Small Anim Pract. 33:573–596. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Owen LN: TNM Classification of Tumours in
Domestic AnimalsWorld Health Organization; Geneva: pp. 531980
|
|
46
|
Lopes JR, Maschio LB, Jardim-Perassi BV,
Moschetta MG, Ferreira LC, Martins GR, Gelaleti GB and De Campos
Zuccari DA: Evaluation of melatonin treatment in primary culture of
canine mammary tumors. Oncol Rep. 33:311–319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lopes J, Arnosti D, Trosko JE, Tai MH and
Zuccari D: Melatonin decreases estrogen receptor binding to
estrogen response elements sites on the OCT4 gene in human breast
cancer stem cells. Genes Cancer. 7:209–217. 2016.PubMed/NCBI
|
|
48
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
49
|
Koeppen HK, Wright BD, Burt AD, Quirke P,
McNicol AM, Dybdal NO, Sliwkowski MX and Hillan KJ: Overexpression
of HER2/neu in solid tumours: An immunohistochimical survey.
Histopathology. 38:96–104. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Remmele W and Stegner HE: Overexpression
of HER2/neu in solid tumours: An immunohistochimical survey.
Pathologe. 8:138–140. 1987.PubMed/NCBI
|
|
51
|
Im KS, Kim NH, Lim HY, Kim HW, Shin JI and
Sur JH: Analysis of a new histological and molecular-based
classification of canine mammary neoplasia. Vet Pathol. 51:549–559.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim NH, Lim HY, Im KS, Kim JH and Sur JH:
Identification of Triple-negative and Basal-like canine mammary
carcinomas using four basal markers. J Comp Pathol. 148:298–306.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
de las Mulas JM, Millán Y and Dios R: A
prospective analysis of immunohistochemically determined estrogen
receptor alpha and progesterone receptor expression and host and
tumor factors as predictors of disease-free period in mammary
tumors of the dog. Vet Pathol. 42:200–212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hewitt SC and Korach KS: Estrogen
receptors: New directions in the new millennium. Endocr Rev.
39:664–675. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fuentes N and Silveyra P: Estrogen
receptor signaling mechanisms. Adv Protein Chem Struct Biol.
116:135–170. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fox EM, Andrade J and Shupnik MA: Novel
actions of estrogen to promote proliferation: Integration of
cytoplasmic and nuclear pathways. Steroids. 74:622–627. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Boonyaratanakornkit V, Hamilton N,
Márquez-Garbán DC, Pateetin P, McGowan EM and Pietras RJ:
Extranuclear signaling by sex steroid receptors and clinical
implications in breast cancer. Mol Cell Endocrinol. 466:51–72.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Vrtačnik P, Ostanek B, Mencej-Bedrač S and
Marc J: The many faces of estrogen signaling. Biochem Med (Zagreb).
24:329–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cortez V, Mann M, Brann DW and Vadlamudi
RK: Extranuclear signaling by estrogen: Role in breast cancer
progression and metastasis. Minerva Ginecol. 62:573–583.
2010.PubMed/NCBI
|
|
60
|
Marino M, Galluzzo P and Ascenzi P:
Estrogen signaling multiple pathways to impact gene transcription.
Curr Genomics. 7:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Poulard C, Treilleux I, Lavergne E,
Bouchekioua-Bouzaghou K, Goddard-Léon S, Chabaud S, Trédan O, Corbo
L and Le Romancer M: Activation of rapid oestrogen signalling in
aggressive human breast cancers. EMBO Mol Med. 4:1200–1213. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Rutteman GR, Misdorp W, Misdorp W,
Blankenstein MA and van den Brom WE: Oestrogen (ER) and progestin
receptors (PR) in mammary tissue of the female dog: Different
receptor profile in non-malignant and malignant states. Br J
Cancer. 58:594–599. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Donnay I, Rauis J, Devleeschouwer N,
Wouters-Ballman P, Leclercq G and Verstegen J: Comparison of
estrogen and progesterone receptor expression in normal and tumor
mammary tissues from dogs. Am J Vet Res. 56:1188–1194.
1995.PubMed/NCBI
|
|
64
|
Peña L, Perez-Alenza MD, Rodriguez-Bertos
A and Nieto A: Canine inflammatory mammary carcinoma:
Histopathology, immunohistochemistry and clinical implications of
21 cases. Breast Cancer Res Treat. 78:141–148. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Millanta F, Calandrella M, Bari G,
Niccolini M, Vannozzi I and Poli A: Comparison of steroid receptor
expression in normal, dysplastic, and neoplastic canine and feline
mammary tissues. Res Vet Sci. 79:225–232. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chang CC, Tsai MH, Liao JW, Chan JP, Wong
ML and Chang SC: Evaluation of hormone receptor expression for use
in predicting survival of female dogs with malignant mammary gland
tumors. J Am Vet Med Assoc. 235:391–396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Dutra AP, Granja NV, Schmitt FC and
Cassali GD: c-erbB-2 expression and nuclear pleomorphism in canine
mammary tumors. Brazilian J Med Biol Res. 37:1673–1681. 2004.
View Article : Google Scholar
|
|
69
|
Campos LC, Silva JO, Santos FS, Araújo MR,
Lavalle GE, Ferreira E and Cassali GD: Prognostic significance of
tissue and serum HER2 and MUC1 in canine mammary cancer. J Vet
Diagn Invest. 27:531–535. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Klopfleisch R, von Euler H, Sarli G, Pinho
SS, Gärtner F and Gruber AD: Molecular carcinogenesis of canine
mammary tumors: News from an old disease. Vet Pathol Online.
48:98–116. 2011. View Article : Google Scholar
|
